
|Articles|August 18, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
Future Immune Checkpoint Strategies
Author(s)James P. Allison, PhD
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Advertisement
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Learn about the history of immunotherapy > >
Articles in this issue
almost 12 years ago
A Brief History of Immunotherapyalmost 12 years ago
Better Biomarker Testing Needed in Immuno-Oncologyalmost 12 years ago
Autoimmunity and Limitations of Cancer Vaccinesalmost 12 years ago
Combining Immunotherapies With Targeted Therapies and Other Immunotherapiesalmost 12 years ago
The Management of Side Effects Associated With Immunotherapiesalmost 12 years ago
The Next Wave in Immunotherapy: CombinationsAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































